Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06881251 · ClinicalTrials.gov registry record · Phase 2

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

A Phase 2 study of Dermatitis, Atopic, sponsored by Janssen Research & Development.

Active
Registry status
Phase 2
Development phase
256
Enrollment target
20
Study locations

NCT06881251 is a Phase 2 study of Dermatitis, Atopic that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 256 participants, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06881251, a Phase 2 study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
256 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Conditions Studied

Dermatitis, Atopic

Interventions

  • DRUG Placebo
  • DRUG Dupilumab
  • DRUG JNJ-95475939

Study Locations (20)

Other

  • CIPREC - Buenos Aires
  • INAER - Investigación en Alergias y Enfermedades Respiratorias - Buenos Aires
  • Instituto de Neumonologia y Dermatologia - Buenos Aires
  • Derma Internacional S A - Buenos Aires
  • Ceti - Centro de Estudos Em Terapias Inovadoras - Curitiba
  • Hospital De Clinicas De Porto Alegre - Porto Alegre
  • Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP - Ribeirão Preto

Texas

  • Arlington Center for Dermatology - Arlington
  • Center for Clinical Studies - Houston
  • Progressive Clinical Research - San Antonio

California

  • First OC Dermatology - Fountain Valley
  • University of California Los Angeles - Division of Dermatology - Los Angeles

Indiana

  • Dawes Fretzin Clinical Research Group LLC - Indianapolis
  • Indiana Clinical Trial Center - Plainfield

Georgia

  • Hamilton Research LLC - Alpharetta

Illinois

  • DeNova Research - Chicago

North Dakota

  • Red River Research Partners LLC - Fargo

Ohio

  • Optima Research - Boardman

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2025-02-26
Est. Completion 2026-03-26
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06881251

The ClinicalTrials.gov registry entry for NCT06881251 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (34% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06881251 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06881251 about?

NCT06881251 is a clinical study titled "A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)". The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

What is the current status of trial NCT06881251?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2025-02-26. Estimated completion is 2026-03-26.

What conditions does trial NCT06881251 study?

This clinical trial studies the following conditions: Dermatitis, Atopic.

What interventions are being tested in trial NCT06881251?

The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), JNJ-95475939 (DRUG).

Who is sponsoring clinical trial NCT06881251?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06881251 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dermatitis, Atopic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dermatitis, Atopic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.